A
Acumen Pharmaceuticals, Inc. (ABOS)
NMS – Real Time Price. Currency in USD
2.36
+0.15 (6.79%)
At close: Jun 26, 2026, 4:00 PM EDT
2.26
-0.10 (-4.24%)
After-hours: Jun 26, 2026, 7:53 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
2.36
+0.15 (6.79%)
At close: Jun 26, 2026, 4:00 PM EDT
2.26
-0.10 (-4.24%)
After-hours: Jun 26, 2026, 7:53 PM EDT
Revenue breakdown data has not been calculated yet.
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 4.55 | 6.05 | 10 | |
| Quick ratio | 4.55 | 5.63 | 10 | |
| Debt to Equity | 0.36 | 0.30 | 7.0 | |
| Debt to Assets | 0.23 | 1.04 | 7.0 | |
| Interest coverage | -19.78 | -16.91 | 1.0 | |
| Weighted average score | 7.0 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | -169K | -184K | -178K | -184K | -185K |
| Operating Income | -45M | -61M | -114M | -124M | -115M |
| Net Income | -43M | -52M | -102M | -121M | -113M |
| EBITDA | -45M | -61M | -114M | -124M | -114M |
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Gross margin % | N/A | -11.73 | 1.0 | |
| Operating margin % | N/A | -24.60 | 1.0 | |
| Net margin % | N/A | -172.20 | 1.0 | |
| EBITDA margin % | N/A | -201.27 | 1.0 | |
| Cash flow margin % | N/A | -156.39 | 1.0 | |
| Weighted average score | 1.0 | |||
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | 47.16 | 5.5 |
| Next quarter | N/A | 14.4 | 4.5 |
| Current year | N/A | 28.89 | 5.5 |
| Next year | N/A | -2.77 | 1.0 |
| Weighted average score | 4.1 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | 17.51 | 17.5 | -26.34 | 7.3 |
| Y/Y | 999 | 27.99 | 31.25 | 29.45 | 10 |
| 3y average | 999 | -45.37 | -25.71 | -52.06 | 3.3 |
| 5y average | 779.2 | -270.43 | 0.43 | -78.79 | 3.5 |
| Weighted average score | 6.0 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Company's cash reserves $51.8M significantly exceed its total debt $31.2M, ensuring strong financial flexibility
Total current assets $133.1M exceed Total current liabilities $29.2M, highlighting excellent liquidity
Debt-to-equity ratio (0.4) is well below the industry average (0.3), showcasing prudent financial management
Interest coverage ratio (-19.8x) is dangerously low, suggesting debt repayment risks
Negative free cash flow -$24.1M limits the company's ability to reinvest or pay down debt